|
1
|
Wilusz JE, Sunwoo H and Spector DL: Long
noncoding RNAs: Functional surprises from the RNA world. Genes Dev.
23:1494–1504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Geisler S and Coller J: RNA in unexpected
places: Long non-coding RNA functions in diverse cellular contexts.
Nat Rev Mol Cell Biol. 14:699–712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Prensner JR and Chinnaiyan AM: The
emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dieli-Conwright CM, Lee K and Kiwata JL:
Reducing the risk of breast cancer recurrence: An evaluation of the
effects and mechanisms of diet and exercise. Curr Breast Cancer
Rep. 8:139–150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao Z, Li S, Song E and Liu S: The roles
of ncRNAs and histone-modifiers in regulating breast cancer stem
cells. Protein Cell. 7:89–99. 2016. View Article : Google Scholar :
|
|
6
|
Cojocneanu Petric R, Braicu C, Raduly L,
Zanoaga O, Dragos N, Monroig P, Dumitrascu D and Berindan-Neagoe I:
Phytochemicals modulate carcinogenic signaling pathways in breast
and hormone-related cancers. Onco Targets Ther. 8:2053–2066. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu X, Feng Y, Zhang D, Zhao SD, Hu Z,
Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, et al: A functional
genomic approach identifies FAL1 as an oncogenic long noncoding RNA
that associates with BMI1 and represses p21 expression in cancer.
Cancer Cell. 26:344–357. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rinn JL and Chang HY: Genome regulation by
long noncoding RNAs. Annu Rev Biochem. 81:145–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takenaka K, Chen BJ, Modesitt SC, Byrne
FL, Hoehn KL and Janitz M: The emerging role of long non-coding
RNAs in endometrial cancer. Cancer Genet. 209:445–455. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen QN, Wei CC, Wang ZX and Sun M: Long
non-coding RNAs in anti-cancer drug resistance. Oncotarget.
8:1925–1936. 2016.PubMed/NCBI
|
|
11
|
Jaouen A, Thivolet-Bejui F, Chalabreysse
L, Piaton E, Traverse-Glehen A, Isaac S, Decaussin-Petrucci M,
Depaepe L, Fontaine J, Remy I, et al: BRCA1 associated protein 1
(BAP1) expression in pleural diffuse malignant mesothelioma: A
comparative cytological and histological analyses on 50 patients.
Ann Pathol. 36:111–119. 2016.In French. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Minardi D, Lucarini G, Milanese G, Di
Primio R, Montironi R and Muzzonigro G: Loss of nuclear BAP1
protein expression is a marker of poor prognosis in patients with
clear cell renal cell carcinoma. Urol Oncol. 34:338.e11–338.e18.
2016. View Article : Google Scholar
|
|
13
|
Nickerson ML, Dancik GM, Im KM, Edwards
MG, Turan S, Brown J, Ruiz-Rodriguez C, Owens C, Costello JC, Guo
G, et al: Concurrent alterations in TERT, KDM6A, and the BRCA
pathway in bladder cancer. Clin Cancer Res. 20:4935–4948. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sahtoe DD, van Dijk WJ, Ekkebus R, Ovaa H
and Sixma TK: BAP1/ASXL1 recruitment and activation for H2A
deubiquitination. Nat Commun. 7:102922016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, He L, Du Y, Zhu P, Huang G, Luo J,
Yan X, Ye B, Li C, Xia P, et al: The long noncoding RNA lncTCF7
promotes self-renewal of human liver cancer stem cells through
activation of Wnt signaling. Cell Stem Cell. 16:413–425. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bharathy N, Suriyamurthy S, Rao VK, Ow JR,
Lim HJ, Chakraborty P, Vasudevan M, Dhamne CA, Chang KT, Min VL, et
al: P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar
rhabdomyosarcoma. J Pathol. 240:269–281. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wagle M, Eiring AM, Wongchenko M, Lu S,
Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, et al:
A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor
resistance in chronic myeloid leukemia. Leukemia. 30:1493–1501.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Szydlowski M, Kiliszek P, Sewastianik T,
Jablonska E, Bialopiotrowicz E, Gorniak P, Polak A, Markowicz S,
Nowak E, Grygorowicz MA, et al: FOXO1 activation is an effector of
SYK and AKT inhibition in tonic BCR signal-dependent diffuse large
B-cell lymphomas. Blood. 127:739–748. 2016. View Article : Google Scholar
|
|
19
|
Kim JH, Choi JS and Lee BH: PI3K/Akt and
MAPK pathways evoke activation of FoxO transcription factor to
undergo neuronal apoptosis in brain of the silkworm Bombyx mori
(Lepidoptera: Bombycidae). Cell Mol Biol (Noisy-le-grand). (Suppl
58): OL1780–OL1785. 2012.
|
|
20
|
Lian R, Lu B, Jiao L, Li S, Wang H, Miao W
and Yu W: MiR-132 plays an oncogenic role in laryngeal squamous
cell carcinoma by targeting FOXO1 and activating the PI3K/AKT
pathway. Eur J Pharmacol. 792:1–6. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeng YB, Liang XH, Zhang GX, Jiang N,
Zhang T, Huang JY, Zhang L and Zeng XC: miRNA-135a promotes
hepatocellular carcinoma cell migration and invasion by targeting
forkhead box O1. Cancer Cell Int. 16:632016. View Article : Google Scholar : PubMed/NCBI
|
